Levi & Korsinsky Encourages uniQure N.V. Investors to Join Class Action Lawsuit
In a significant development for investors in uniQure N.V. (NASDAQ: QURE), Levi & Korsinsky LLP has announced the initiation of a class action lawsuit aimed at addressing potential securities fraud that impacted shareholders. This legal action arises from events between September 24, 2025, and October 31, 2025, during which time investors may have suffered financial losses due to misleading statements related to the company's operations.
The lawsuit arises from allegations directed at uniQure’s management regarding the conduct of its clinical trials and the integrity of its disclosures. Specifically, the complaint claims that the defendants made false or misleading statements concerning the company's Pivotal Study—critical research that was supposed to present promising results for its product. It is asserted that the study's design lacked complete approval from the FDA (Food and Drug Administration), raising concerns about the validity of the results reported by the company.
Moreover, despite the initial claims of success, the lawsuit suggests that uniQure was aware that it would likely need to delay its Biologics License Application (BLA) to undergo further studies, which contradicted prior assertions made to investors. These alleged omissions and misrepresentations led to a misinformed understanding of the company’s business prospects, which investors relied on for making informed financial decisions.
For individuals who have faced financial setbacks due to their investments in uniQure during the specified window, it is crucial to act promptly. The court has set a deadline of April 13, 2026, for filing a request to be appointed as lead plaintiff in this case. However, rest assured that participation in the lawsuit does not necessitate serving as a lead plaintiff; any affected investor may still be eligible for settlements without additional costs.
The experienced attorneys at Levi & Korsinsky are advocating for affected investors, drawing upon two decades of successful litigation in similar matters. Their extensive expertise has bolstered their reputation, as seen in their six consecutive years ranked within the Top 50 firms for securities litigation in the United States.
Investors wishing to participate in this class action lawsuit are encouraged to reach out to Levi & Korsinsky promptly. Options to get in touch include direct communication with attorney Joseph E. Levi at [insert email] or by calling (212) 363-7500. More information about the class action can also be accessed through their dedicated submission link.
The firm ensures that there are no out-of-pocket fees to join the class action, making it accessible for those who believe they have a claim. Levi & Korsinsky aims to assist investors in recovering losses incurred during this challenging period, reinforcing their commitment to providing justice for shareholders who have been wronged.
In conclusion, if you invested in uniQure N.V. and felt the impact of misleading information regarding the company’s drug trials and application processes, now is the time to seek help from qualified legal professionals. Your chance to reclaim potential losses lies within your reach as Levi & Korsinsky PLL confidently navigates the complexities of securities litigation on behalf of affected investors.
Background of the Case
The lawsuit arises from allegations directed at uniQure’s management regarding the conduct of its clinical trials and the integrity of its disclosures. Specifically, the complaint claims that the defendants made false or misleading statements concerning the company's Pivotal Study—critical research that was supposed to present promising results for its product. It is asserted that the study's design lacked complete approval from the FDA (Food and Drug Administration), raising concerns about the validity of the results reported by the company.
Moreover, despite the initial claims of success, the lawsuit suggests that uniQure was aware that it would likely need to delay its Biologics License Application (BLA) to undergo further studies, which contradicted prior assertions made to investors. These alleged omissions and misrepresentations led to a misinformed understanding of the company’s business prospects, which investors relied on for making informed financial decisions.
What Investors Need to Know
For individuals who have faced financial setbacks due to their investments in uniQure during the specified window, it is crucial to act promptly. The court has set a deadline of April 13, 2026, for filing a request to be appointed as lead plaintiff in this case. However, rest assured that participation in the lawsuit does not necessitate serving as a lead plaintiff; any affected investor may still be eligible for settlements without additional costs.
The experienced attorneys at Levi & Korsinsky are advocating for affected investors, drawing upon two decades of successful litigation in similar matters. Their extensive expertise has bolstered their reputation, as seen in their six consecutive years ranked within the Top 50 firms for securities litigation in the United States.
How to Get Involved
Investors wishing to participate in this class action lawsuit are encouraged to reach out to Levi & Korsinsky promptly. Options to get in touch include direct communication with attorney Joseph E. Levi at [insert email] or by calling (212) 363-7500. More information about the class action can also be accessed through their dedicated submission link.
The firm ensures that there are no out-of-pocket fees to join the class action, making it accessible for those who believe they have a claim. Levi & Korsinsky aims to assist investors in recovering losses incurred during this challenging period, reinforcing their commitment to providing justice for shareholders who have been wronged.
In conclusion, if you invested in uniQure N.V. and felt the impact of misleading information regarding the company’s drug trials and application processes, now is the time to seek help from qualified legal professionals. Your chance to reclaim potential losses lies within your reach as Levi & Korsinsky PLL confidently navigates the complexities of securities litigation on behalf of affected investors.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.